Select Topic:
Browse by Series:

Nivolumab in HNSCC

Insights From: Ezra Cohen, MD, Moores Cancer Center; UC San Diego Health; Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
Published: Tuesday, Jul 18, 2017



Transcript:

Jared Weiss, MD:
CheckMate-141 was an important study, both for nivolumab and for the overall PD-1 and PD-L1 story in head and neck cancer. This study randomized patients with second-line recurrent metastatic head and neck cancer to nivolumab, a PD-1 inhibitor, or to the investigator’s choice of the second-line agents methotrexate, docetaxel, or cetuximab—which are the choices considered in the real world. We now have survival data from that study: improvements from 5 to 7.5 months with the use of nivolumab, with a favorable, but different, toxicity profile—very consistent with the other PD-1 and PD-L1 agents.

What’s unique about this study is that it’s randomized. We have actual randomized data, at least in the second-line setting now, to show the superiority of the PD-1 agent over chemotherapy. This is very analogous to what we already had in the lung cancer situation. As a result of the CheckMate-141 study, nivolumab can be considered a standard second-line agent in recurrent metastatic head and neck cancer.

Ezra Cohen, MD: When we look at anti-PD-1 therapies in comparison to standard therapy, we really have 1 randomized trial to examine. That is the CheckMate-141 trial that compared nivolumab to single-agent standard therapy in patients who are platinum-refractory with recurrent metastatic squamous cell carcinoma of the head and neck. What that study clearly showed was that nivolumab met its primary endpoint—improved survival. In fact, it showed a doubling 1-year survival rate from 17% to 36%, an increased response rate, and an increased median progression-free survival, with a tail on the PFS curve as well. It’s clear, from level 1 evidence, that an anti-PD-1 antibody—in this case, nivolumab—is superior to standard of care in this setting.

Transcript Edited for Clarity
Slider Left
Slider Right


Transcript:

Jared Weiss, MD:
CheckMate-141 was an important study, both for nivolumab and for the overall PD-1 and PD-L1 story in head and neck cancer. This study randomized patients with second-line recurrent metastatic head and neck cancer to nivolumab, a PD-1 inhibitor, or to the investigator’s choice of the second-line agents methotrexate, docetaxel, or cetuximab—which are the choices considered in the real world. We now have survival data from that study: improvements from 5 to 7.5 months with the use of nivolumab, with a favorable, but different, toxicity profile—very consistent with the other PD-1 and PD-L1 agents.

What’s unique about this study is that it’s randomized. We have actual randomized data, at least in the second-line setting now, to show the superiority of the PD-1 agent over chemotherapy. This is very analogous to what we already had in the lung cancer situation. As a result of the CheckMate-141 study, nivolumab can be considered a standard second-line agent in recurrent metastatic head and neck cancer.

Ezra Cohen, MD: When we look at anti-PD-1 therapies in comparison to standard therapy, we really have 1 randomized trial to examine. That is the CheckMate-141 trial that compared nivolumab to single-agent standard therapy in patients who are platinum-refractory with recurrent metastatic squamous cell carcinoma of the head and neck. What that study clearly showed was that nivolumab met its primary endpoint—improved survival. In fact, it showed a doubling 1-year survival rate from 17% to 36%, an increased response rate, and an increased median progression-free survival, with a tail on the PFS curve as well. It’s clear, from level 1 evidence, that an anti-PD-1 antibody—in this case, nivolumab—is superior to standard of care in this setting.

Transcript Edited for Clarity
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x